CGON Earnings Date: Nov 13, 2026 (Estimated) — CG Oncology Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CGON's next earnings date?
CG Oncology Inc. (CGON) is expected to report Q3 2026 earnings on Friday, November 13, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.83 on revenue of $547,684.
How did CGON do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), CG Oncology Inc. posted EPS of -$0.90 versus the -$0.66 estimate, a miss of 38.5%. Revenue was $1.2M against a $360,805 estimate. The stock's 1-day post-earnings move was +3.4%.
How much does CGON stock move after earnings?
CGON beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.0% (up or down) in the day after earnings.
About CG Oncology Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.66 | -0.90 | -38.46% | $1.2M | ❌ Miss | +3.36% | +6.31% | +2.64% |
| 2026-05-08 | Q1 2026 | -0.55 | -0.71 | -29.09% | $1.1M | ❌ Miss | +0.64% | +0.51% | -21.36% |
| 2026-02-27 | Q4 2025 | -0.59 | -0.51 | +13.56% | $2.3M | ✅ Beat | +4.79% | +7.59% | +15.17% |
| 2025-11-14 | Q3 2025 | -0.56 | -0.57 | -1.79% | $1.7M | ❌ Miss | +8.61% | +7.81% | +5.27% |
| 2025-08-08 | Q2 2025 | -0.46 | -0.54 | -17.39% | $0 | ❌ Miss | +2.05% | +6.61% | +38.36% |
| 2025-05-13 | Q1 2025 | -0.28 | -0.45 | -60.71% | $52,000 | ❌ Miss | -3.90% | -1.19% | +4.05% |
| 2025-03-28 | Q4 2024 | -0.39 | -0.46 | -17.95% | $456,000 | ❌ Miss | -1.93% | -30.44% | +3.82% |
| 2024-11-12 | Q3 2024 | -0.36 | -0.30 | +16.67% | $0 | ✅ Beat | -6.83% | -16.33% | -20.06% |
Showing last 8 quarters.